Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in metastatic Merkel cell carcinoma
ISRCTN10125877Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in Merkel cell carcinoma (MCC), sponsored by University of Birmingham. Primary endpoint: Clinical response rate. Started Dec 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on ISRCTN10125877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10125877.